What's new

Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Status: Opinion

Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Status: Opinion

Apr 25, 2025 - 15:03
 0
Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Status: Opinion
Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Status: Opinion
Read More

Tags:

Previous Article

Orphan designation: diflunisal Treatment of ATTR amyloidosis, 21/06/2022 Positive

Next Article

Human medicines European public assessment report (EPAR): Oczyesa, octreotide, S...

Related Posts

Human medicines European public assessment report (EPAR): Afqlir, aflibercept, Date of authorisation: 13/11/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 25, 2025  0

Human medicines European public assessment report (EPAR): Micardis, telmisartan, Date of authorisation: 16/12/1998, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 23, 2025  0

Summary of opinion: Zoonotic Influenza Vaccine Seqirus, 25/04/2025 Positive

Summary of opinion: Zoonotic Influenza Vaccine Seqirus,...

Apr 25, 2025  0